CEL SCI CORP 8-K — AI Bull & Bear Analysis

CEL-SCI's 8-K filing confirms the closing of a $7.2 million common stock offering intended to fund the development of Multikine and general corporate operations. While the infusion of cash provides a necessary lifeline for the biotech firm's research and development, it comes at the cost of significant dilution for existing shareholders. The overall impact is a temporary stabilization of the company's runway, though investors must now weigh the benefit of continued clinical progress against the risks of a low-priced offering and the eventual expiration of insider lock-up periods.